Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Dermatologic 2Thoracic 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Genitourinary 1Classical hematology 1

Conditions

Neoplasms 2Melanoma 2Neoplasms by Site 1Neoplasms by Histologic Type 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42Specimen Handling 42atezolizumab 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × HuMax-IL8 × Dermatologic × Clear all
NCT03400332 2026-02-24

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Bristol-Myers Squibb

Phase 1/2 Completed
281 enrolled 44 charts
Dermatologic

Melanoma, Neoplasms

NCT04572451 2025-08-01

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

University of Pittsburgh

Phase 1 Recruiting
50 enrolled
Dermatologic

Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon âš¡